Skip to main content Skip to section navigation Skip to footer
News Careers Contact us
Immunocore Holdings plc
  • About Us
    • Overview
    • Management Team
    • Board of Directors
    • Our Values
    • Compliance and Transparency
  • Pipeline & Portfolio
    • Pipeline
    • Our Therapies
  • Science
    • Overview
    • Publications
  • Clinical Trials
  • Investors
    • Overview
    • News
    • Events & Presentations
    • Stock Info
    • Financials & Filings
    • Governance
    • IR Resources
  • Medical Information
    • Request medical information
    • US healthcare professionals
    • Grants and funding
  • News
  • Careers
  • Contact us

Presentations

Investors

Investors

  • Overview
  • News
    • Press Releases
    • Email Alerts
  • Events & Presentations
    • Events
    • Presentations
  • Stock Info
    • Quote and Chart
    • Historical Performance
    • Analyst Coverage
  • Financials & Filings
    • Financial Results
    • SEC Filings
    • Annual Reports
    • Email Alerts
  • Governance
    • Overview
    • Governance Documents
    • Management Team
    • Board of Directors
    • Board Committees
  • IR Resources
    • Investor FAQs
    • Email Alerts
    • Contacts
  • Events & Presentations

  • Events
  • Presentations

Corporate Presentation - May 2025

IMC-M113V Phase 1 MAD Data Q1 2025

PRAME Phase 1 Cutaneous Melanoma Data – ASCO 2024

Initial Phase 1 Data from PRAME Program (ESMO Presentation)

rss_feed RSS
  • emailEmail Alerts
  • contact_pageContacts
  • rss_feedRSS News Feed
  • account_treeSitemap
Immunocore Holdings plc
  • Visit us on Linkedin
  • Visit us on Youtube
©2025 Immunocore Holdings plc. All Rights Reserved.
Disclaimer Sitemap Compliance and Transparency Terms and Conditions
Privacy and Social Media Guidelines Cookies Payments and Disclosures
Clinical Trials Gender Pay Gap Report Modern Slavery Statement Manage Cookie Preferences

This is Immunocore's global website, intended for visitors seeking information on Immunocore's worldwide business.

If you are a medical professional and would like further information about Immunocore, our clinical research or clinical trials, please send an email to medical.information@immunocore.com (US) or medinfo.eu@immunocore.com (outside of US).

CM-GL-TAX-2400001
Date of production: April 2024